Burnham G
Department of International Health, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland, USA.
Am J Trop Med Hyg. 1995 Mar;52(3):270-6. doi: 10.4269/ajtmh.52-270.
To determine effects of ivermectin on skin lesions of onchocerciasis, a placebo-controlled, double-blind trial was carried out in the Thyolo highlands of Malawi involving 70 persons over a 32-month period. Assessment was made using both a clinical numeric grading system and sequential photographs. Among both ivermectin and placebo recipients, there was a significant reduction in both the severity and extent of papular skin lesions. Persons with edematous or lichenified skin lesions of onchocerciasis who received ivermectin showed significantly more improvement than those receiving placebo. Twelve months after the placebo group received ivermectin, their skin lesions were similar to those of the ivermectin group. Changes were most evident for those persons with more severe skin disease in both the ivermectin and placebo groups. Annual ivermectin treatment for onchocercal skin lesions is probably inadequate, and treatment three or four times a year may be required, although the optimum regimen has not been established.
为确定伊维菌素对盘尾丝虫病皮肤病变的影响，在马拉维的蒂约洛高地进行了一项为期32个月的安慰剂对照双盲试验，涉及70人。使用临床数字评分系统和系列照片进行评估。在接受伊维菌素和安慰剂的人群中，丘疹性皮肤病变的严重程度和范围均显著降低。患有盘尾丝虫病水肿性或苔藓化皮肤病变且接受伊维菌素治疗的人比接受安慰剂的人改善更为显著。安慰剂组接受伊维菌素治疗12个月后，其皮肤病变与伊维菌素组相似。伊维菌素组和安慰剂组中皮肤疾病较严重的人群变化最为明显。每年使用伊维菌素治疗盘尾丝虫性皮肤病变可能并不充分，可能需要每年治疗三到四次，尽管尚未确定最佳治疗方案。
